Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Marketing & Communications
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
May 29, 2009
Dey concludes the three-year agreement with Bristol-Myers
Ocimum Biosolutions to Introduce New Test for the H1N1 Flu
May 04, 2009
Launches a Microarray Based Test Updated With the Latest H1N1 Sequences
New Botox(R) Alternative Dysport(TM) FDA Approved
April 30, 2009
Ready to Rumble
Duramed Launches LoSEASONIQUE(TM) Oral Contraceptive
April 30, 2009
A New Lower-Dose, Extended-Cycle Oral Contraceptive for the Prevention of Pregnancy
Seegene Introduces Diagnostic Test for Diarrhea
April 29, 2009
Seeplex(R) Diarrhea ACE Detection Tests for 14 Diarrhea Causing Pathogens
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer
April 14, 2009
Pivotal Phase 3 IMPACT Study Meets Primary Endpoint
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and CEO
April 08, 2009
Alan L. Crane named Chairman of the Board
Latest News
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Most Popular
Most Emailed
Most Recent
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
FDA Approves Exalgo Extended-Release Tablets
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
CSL Behring Receives FDA Approval of Hizentra™
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Portola Pharmaceuticals Announces Senior Management and Board Changes
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development